Daniele Raggi

5.1k total citations
177 papers, 2.0k citations indexed

About

Daniele Raggi is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniele Raggi has authored 177 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Surgery, 80 papers in Oncology and 60 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniele Raggi's work include Bladder and Urothelial Cancer Treatments (98 papers), Cancer Immunotherapy and Biomarkers (68 papers) and Urinary and Genital Oncology Studies (61 papers). Daniele Raggi is often cited by papers focused on Bladder and Urothelial Cancer Treatments (98 papers), Cancer Immunotherapy and Biomarkers (68 papers) and Urinary and Genital Oncology Studies (61 papers). Daniele Raggi collaborates with scholars based in Italy, United States and Canada. Daniele Raggi's co-authors include Andrea Necchi, Patrizia Giannatempo, Roberto Salvioni, Maurizio Colecchia, Nicola Nicolai, Luigi Mariani, Laura Marandino, Francesco Montorsi, Alberto Briganti and Mario Catanzaro and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Daniele Raggi

168 papers receiving 2.0k citations

Peers

Countries citing papers authored by Daniele Raggi

Since Specialization

Citations

This map shows the geographic impact of Daniele Raggi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniele Raggi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniele Raggi more than expected).

Fields of papers citing papers by Daniele Raggi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniele Raggi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniele Raggi. The network helps show where Daniele Raggi may publish in the future.

Co-authorship network of co-authors of Daniele Raggi

This figure shows the co-authorship network connecting the top 25 collaborators of Daniele Raggi. A scholar is included among the top collaborators of Daniele Raggi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniele Raggi. Daniele Raggi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HER2 and urothelial carcinoma: current understanding and future directions 2025 ·Nature Reviews Urology ·Daniele Raggi, (unknown), Filippo Pederzoli, Alberto Martini, (unknown), Omar Alhalabi, Peter H. O’Donnell, Jeffrey S. Ross, Shilpa Gupta, Ashish M. Kamat, Bishoy M. Faltas, Peter C. Black, Philippe E. Spiess, Petros Grivas, Jianjun Gao, Andrea B. Apolo, Robert Huddart, Andrea Necchi, Matthew D. Galsky	1
2	Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer 2024 ·European Urology Oncology ·Roger Li, Luigi Nocera, Kyle Rose, Daniele Raggi, (unknown), (unknown), (unknown), Valentina Tateo, (unknown), G. Daniel Grass, Scott M. Gilbert, Wade J. Sexton, (unknown), Marco Moschini, Alberto Briganti, Francesco Montorsi, Philippe E. Spiess, Andrea Necchi	8
3	Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials. 2024 ·Journal of Clinical Oncology ·(unknown), Giuseppe Basile, (unknown), Daniele Raggi, Valentina Tateo, (unknown), (unknown), Maurizio Colecchia, Renzo Colombo, (unknown), Chiara Re, Alberto Briganti, Francesco Montorsi, Andrea Necchi	0
4	First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC). 2024 ·Journal of Clinical Oncology ·(unknown), Giuseppe Basile, Daniele Raggi, (unknown), Valentina Tateo, (unknown), (unknown), (unknown), Maurizio Colecchia, Renzo Colombo, Marco Moschini, Chiara Re, (unknown), Giorgio Brembilla, Francesco De Cobelli, Alberto Briganti, Dean C. Pavlick, Jeffrey S. Ross, Francesco Montorsi, Andrea Necchi	1
5	A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study 2023 ·Critical Reviews in Oncology/Hematology ·Giorgio Bogani, Michela Cinquini, Diego Signorelli, Elio Gregory Pizzutilo, (unknown), Melissa Bersanelli, Daniele Raggi, Salvatore Alfieri, Sebastiano Buti, Federica Bertolini, Pierluigi Bonomo, Laura Marandino, Mimma Rizzo, Marta Monteforte, Marco Maria Aiello, Antonino Carmelo Tralongo, Valter Torri, Violante Di Donato, Patrizia Giannatempo	15
6	Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy 2023 ·World Journal of Urology ·Giuseppe Rosiello, (unknown), Alessandro Larcher, Giuseppe Fallara, (unknown), Giuseppe Basile, Chiara Re, Zhe Tian, Pierre I. Karakiewicz, Alexandre Mottrie, Francesco Trevisani, Laura Marandino, Daniele Raggi, Andrea Necchi, Roberto Bertini, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Umberto Capitanio	2
7	Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer 2023 ·European Urology Open Science ·Giuseppe Fallara, Daniele Robesti, Daniele Raggi, Francesco Montorsi, Andrea Necchi, Matthew R. Cooperberg, (unknown), Guillaume Ploussard, Alberto Martini	5
8	Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial 2022 ·Clinical Cancer Research ·Giuseppe Basile, Marco Bandini, Ewan A. Gibb, Jeffrey S. Ross, Daniele Raggi, Laura Marandino, (unknown), (unknown), Renzo Colombo, Maurizio Colecchia, Roberta Lucianò, Luigi Nocera, Marco Moschini, Alberto Briganti, Francesco Montorsi, Andrea Necchi	64
9	Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence 2022 ·Current Problems in Cancer ·Umberto Capitanio, Giuseppe Fallara, Daniele Raggi, Luigi Nocera, Alessandro Larcher, Federico Belladelli, Isaline Rowe, Alberto Briganti, Andrea Salonia, Pierre I. Karakiewicz, Francesco Montorsi, Alberto Martini, Andrea Necchi	2
10	Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis 2022 ·Critical Reviews in Oncology/Hematology ·Giuseppe Fallara, Federico Belladelli, Daniele Robesti, Daniele Raggi, Luigi Nocera, Laura Marandino, Matthew D. Galsky, Francesco Montorsi, (unknown), Guillaume Ploussard, Andrea Necchi, Alberto Martini	3
11	Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group) 2021 ·Immunotherapy ·Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo, Daniele Raggi, (unknown), Marco Maruzzo, Umberto Basso, Ugo De Giorgi, Francesca Vignani, Giuseppe Luigi Banna, Marco Stellato, Rosa Tambaro, Emanuele Naglieri, (unknown), Giuseppe Procopio, Sandro Pignata, Andrea Necchi, Sebastiano Buti	2
12	Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard 2021 ·European Urology Oncology ·Armando Stabile, Antony Pellegrino, Elio Mazzone, Donato Cannoletta, Mario de Angelis, Francesco Barletta, Simone Scuderi, Vito Cucchiara, Giorgio Gandaglia, Daniele Raggi, Andrea Necchi, Pierre I. Karakiewicz, Francesco Montorsi, Alberto Briganti	74
13	Outcome of non-responders to neoadjuvant immunotherapy compared to cisplatin-based chemotherapy before radical cystectomy in muscle-invasive bladder cancer 2020 ·European Urology Open Science ·Marco Bandini, (unknown), Laura Marandino, Simone Scuderi, Filippo Pederzoli, Daniele Raggi, Andrea Salonia, Giorgio Gandaglia, (unknown), Francesco Barletta, (unknown), (unknown), Marco Moschini, Nicola Fossati, Alberto Briganti, Francesco Montorsi, Renzo Colombo, Andrea Necchi, Andrea Gallina	0
14	Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study 2020 ·Annals of Oncology ·Patrizia Giannatempo, Daniele Raggi, Laura Marandino, Marco Bandini, Elena Farè, Giuseppina Calareso, Maurizio Colecchia, Andrea Gallina, Jeffrey S. Ross, Alessandra Alessi, Alberto Briganti, Francesco Montorsi, Russell W. Madison, Andrea Necchi	31
15	773P Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-label, single-arm, phase II ARCADIA trial 2020 ·Annals of Oncology ·Laura Marandino, Daniele Raggi, Patrizia Giannatempo, Giuseppina Calareso, Alessandra Alessi, Maurizio Colecchia, Russell W. Madison, Jeffrey S. Ross, Andrea Necchi	0
16	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT) 2018 ·Bone Marrow Transplantation ·Andrea Necchi, Salvatore Lo Vullo, Simona Secondino, Giovanni Rosti, Manuela Badoglio, Patrizia Giannatempo, Daniele Raggi, Francesco Lanza, Christian Chabannon, Chiara Bonini, Luigi Mariani, Paolo Pedrazzoli	1
17	Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial 2017 ·Annals of Oncology ·Andrea Necchi, Salvatore Lo Vullo, Patrizia Giannatempo, Daniele Raggi, Giuseppina Calareso, (unknown), Flavio Crippa, Marzia Pennati, Nadia Zaffaroni, Federica Perrone, Adele Busico, Maurizio Colecchia, Nicola Nicolai, Luigi Mariani, Roberto Salvioni	31
18	Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis 2016 ·Annals of Oncology ·Andrea Necchi, Gregory R. Pond, Daniele Raggi, Sarah R. Ottenhof, Simon Horenblas, Vincent Khoo, (unknown), Axel Heidenreich, Bernhard J. Eigl, Lucia Nappi, Kazuya Matsumoto, Ulka N. Vaishampayan, (unknown), Patrizia Giannatempo, Daniel M. Geynisman, Mirko Preto, (unknown), Matthew I. Milowsky, Giuseppe Di Lorenzo, Guru Sonpavde	0
19	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma 2016 ·Clinical Genitourinary Cancer ·Guru Sonpavde, Gregory R. Pond, Giuseppe Di Lorenzo, Carlo Buonerba, (unknown), Gaetano Lanzetta, Andrea Necchi, Patrizia Giannatempo, Daniele Raggi, Kazumasa Matsumoto, Toni K. Choueiri, Stephanie A. Mullane, Günter Niegisch, Peter Albers, J.L. Lee, Hiroshi Kitamura, Haruki Kume, Joaquim Bellmunt	1
20	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial 2014 ·Investigational New Drugs ·Andrea Necchi, Patrizia Giannatempo, Luigi Mariani, Elena Farè, Daniele Raggi, Marzia Pennati, Nadia Zaffaroni, Flavio Crippa, Alfonso Marchianò, Nicola Nicolai, Massimo Maffezzini, (unknown), Maria Grazia Daidone, A. M. Gianni, Roberto Salvioni, Filippo de Braud	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact